{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:29:01Z","timestamp":1768822141793,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12325-015-0231-3","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T02:09:00Z","timestamp":1438567740000},"page":"715-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry"],"prefix":"10.1007","volume":"32","author":[{"given":"Felix","family":"Keil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Daikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Skoutelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio Barranco","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashidkhan","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,4]]},"reference":[{"key":"231_CR1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CCM.0B013E318165314B","volume":"36","author":"F Pene","year":"2008","unstructured":"Pene F, Percheron S, Lemiale V, et al. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008;36:690\u20136.","journal-title":"Crit Care Med"},{"issue":"Suppl 5","key":"231_CR2","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","volume":"21","author":"J Naurois de","year":"2010","unstructured":"de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl 5):v252\u20136.","journal-title":"Ann Oncol"},{"key":"231_CR3","doi-asserted-by":"crossref","first-page":"986938","DOI":"10.1155\/2014\/986938","volume":"2014","author":"P Villafuerte-Gutierrez","year":"2014","unstructured":"Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014;2014:986938.","journal-title":"Adv Hematol"},{"key":"231_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2110-5820-1-22","volume":"1","author":"M Legrand","year":"2011","unstructured":"Legrand M, Max A, Schlemmer B, Azoulay E, Gachot B. The strategy of antibiotic use in critically ill neutropenic patients. Ann Intensive Care. 2011;1:22.","journal-title":"Ann Intensive Care"},{"key":"231_CR5","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56\u201393.","journal-title":"Clin Infect Dis"},{"issue":"249\u201356","key":"231_CR6","first-page":"90","volume":"8","author":"KV Rolston","year":"2010","unstructured":"Rolston KV, McConnell SA, Brown J, Lamp KC. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol. 2010;8(249\u201356):90.","journal-title":"Clin Adv Hematol Oncol"},{"key":"231_CR7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","volume":"53","author":"JS Bubalo","year":"2009","unstructured":"Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53:428\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"231_CR8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18\u201355.","journal-title":"Clin Infect Dis"},{"key":"231_CR9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325\u20137.","journal-title":"Clin Infect Dis"},{"key":"231_CR10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/infdis\/jir275","volume":"204","author":"TL Holland","year":"2011","unstructured":"Holland TL, Fowler VG Jr. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J Infect Dis. 2011;204:329\u201331.","journal-title":"J Infect Dis"},{"key":"231_CR11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.4155\/fmc.13.86","volume":"5","author":"N Bionda","year":"2013","unstructured":"Bionda N, Pitteloud JP, Cudic P. Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria. Future Med Chem. 2013;5:1311\u201330.","journal-title":"Future Med Chem"},{"key":"231_CR12","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1128\/AAC.00738-06","volume":"51","author":"Mortin Li","year":"2007","unstructured":"Li Mortin, Li T, Van Praagh AD, et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother. 2007;51:1787\u201394.","journal-title":"Antimicrob Agents Chemother"},{"key":"231_CR13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","volume":"55","author":"JN Steenbergen","year":"2005","unstructured":"Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005;55:283\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"231_CR14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1592\/phco.27.6.927","volume":"27","author":"GR Barber","year":"2007","unstructured":"Barber GR, Lauretta J, Saez R. A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin. Pharmacotherapy. 2007;27:927\u201332.","journal-title":"Pharmacotherapy"},{"key":"231_CR15","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1345\/aph.1K071","volume":"41","author":"KA Mergenhagen","year":"2007","unstructured":"Mergenhagen KA, Pasko MT. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. Ann Pharmacother. 2007;41:1531\u20135.","journal-title":"Ann Pharmacother"},{"key":"231_CR16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jinf.2006.11.007","volume":"54","author":"DD Poutsiaka","year":"2007","unstructured":"Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007;54:567\u201371.","journal-title":"J Infect"},{"key":"231_CR17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00520-013-1947-8","volume":"22","author":"KV Rolston","year":"2014","unstructured":"Rolston KV, Besece D, Lamp KC, et al. Daptomycin use in neutropenic patients with documented Gram-positive infections. Support Care Cancer. 2014;22:7\u201314.","journal-title":"Support Care Cancer"},{"key":"231_CR18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jac\/dkq528","volume":"66","author":"A Gonzalez-Ruiz","year":"2011","unstructured":"Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, et al. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother. 2011;66:912\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"231_CR19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","volume":"31","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794\u2013810.","journal-title":"J Clin Oncol"},{"key":"231_CR20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dks467","volume":"68","author":"PM Dohmen","year":"2013","unstructured":"Dohmen PM, Guleri A, Capone A, et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother. 2013;68:936\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"231_CR21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.idc.2007.08.008","volume":"21","author":"A Antoniadou","year":"2007","unstructured":"Antoniadou A, Giamarellou H. Fever of unknown origin in febrile leukopenia. Infect Dis Clin N Am. 2007;21:1055\u201390.","journal-title":"Infect Dis Clin N Am"},{"key":"231_CR22","first-page":"CD003914","volume":"1","author":"M Paul","year":"2014","unstructured":"Paul M, Dickstein Y, Borok S, Vidal L, Leibovici L. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2014;1:CD003914.","journal-title":"Cochrane Database Syst Rev"},{"key":"231_CR23","first-page":"37","volume":"1","author":"S Alp","year":"2013","unstructured":"Alp S, Akova M. Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis. 2013;1:37\u201343.","journal-title":"Ther Adv Infect Dis"},{"key":"231_CR24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00520-007-0398-5","volume":"16","author":"PG Morris","year":"2008","unstructured":"Morris PG, Hassan T, McNamara M, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia\u2014a cause for concern. Support Care Cancer. 2008;16:1085\u20138.","journal-title":"Support Care Cancer"},{"key":"231_CR25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/500139","volume":"42","author":"B Jaksic","year":"2006","unstructured":"Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597\u2013607.","journal-title":"Clin Infect Dis"},{"key":"231_CR26","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.00350-06","volume":"51","author":"I Raad","year":"2007","unstructured":"Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"231_CR27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1592\/phco.27.8.1189","volume":"27","author":"M Narita","year":"2007","unstructured":"Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189\u201397.","journal-title":"Pharmacotherapy"},{"key":"231_CR28","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","volume":"44","author":"FB Oleson Jr","year":"2000","unstructured":"Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"231_CR29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673\u201381.","journal-title":"Clin Infect Dis"},{"key":"231_CR30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653\u201365.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0231-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T12:53:21Z","timestamp":1498222401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0231-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["231"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0231-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}